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Tobacco  etch  virus  protease  (TEVp)  is  a  unique  endopeptidase  with  stringent  substrate  speciﬁcity.  TEVp
has been  widely  used  as a puriﬁed  protein  for in vitro  applications,  but also as  a biological  tool  directly
expressing  it  in  living  cells.  To adapt  the  protease  to diverse  applications,  several  TEVp  mutants  with
different  stability  and  enzymatic  properties  have been  reported.  Herein  we  describe  the development  of
a novel  engineered  TEVp  mutant  designed  to be  active  in the secretory  pathway.  While  wild type  TEVp
targeted  to the  secretory  pathway  of  mammalian  cells  is  synthetized  as  an  N-glycosylated  and  catalyti-
cally inactive  enzyme,  a TEVp  mutant  with  selected  mutations  at two  veriﬁed  N-glycosylation  sites  and
at  an  exposed  cysteine  was  highly  efﬁcient.  This  mutant  was  very  active  in the  endoplasmic  reticulumlycosylation
R
RAD
ecretory pathway
(ER)  of  living  cells  and  can  be  used  as a biotechnological  tool  to cleave  proteins  within  the  secretory
pathway.  As  an immediate  practical  application  we  report  the expression  of  a complete  functional  mon-
oclonal  antibody  expressed  from  a single  polypeptide,  which  was  cleaved  by our  TEVp  mutant  into  the
two antibody  chains  and  secreted  as  an assembled  and  functional  molecule.  In  addition,  we show  active
TEVp  mutants  lacking  auto-cleavage  activity.
©  2015  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND. Introduction
In tobacco etch virus part of the Nuclear Inclusion a (NIa) gene
ncodes a 27 kDa protease named tobacco etch virus protease
TEVp) (Dougherty and Parks, 1991). TEVp is homologous to serine-
roteases but, unlike them, it has a cysteine residue (C151) in its
atalytic site. Indeed, the single point mutation C151A completely
bolishes protease activity (Parks et al., 1995).
The minimal TEVp substrate speciﬁcity is encoded in the seven
mino acid long sequence EXXYXQ-S/G (TEVp cleavage Site, TS)
here X can be any amino acid (Dougherty et al., 1988). Up
o now, despite this apparent low speciﬁcity and the variety of
eptides that could be included as TS, the best recognized and
leaved TS is identical to the protease’s natural substrate pep-
ide (ENLYFQ-G/S) (Kostallas et al., 2011). The proteolytic cleavage
∗ Corresponding author.
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egole 101, Mattarello 38123, Italy.
E-mail addresses: burrone@icgeb.org, gianluca.petris@unitn.it (G. Petris).
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ttp://dx.doi.org/10.1016/j.jbiotec.2015.08.026
168-1656/© 2015 The Authors. Published by Elsevier B.V. This is an open access article 
/).license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
occurs between Q and the short aliphatic G or S residue (Parks
et al., 1994). A TS with the sequence GHKVFM/S is also present
in the protease’s C-terminal portion between residues 213–219,
which is intramolecularly recognised and cleaved at M218 (Kapust
et al., 2001; Parks et al., 1995). Conﬂicting results exist on the
proteolytic activity of the auto-cleaved protein fragment (Kapust
et al., 2001; Nunn et al., 2005; Parks et al., 1995). To overcome the
problem of auto-cleavage, several TEVp mutants of amino acid 219
have been characterized (Kapust et al., 2001). Reduced activity of
the auto-cleaved protein has been associated to inhibitory prop-
erties of the cleaved C-terminal end (amino acids 219–242) that
depended on residues 235–242, which were supposed to tightly
bind to the active site (Nunn et al., 2005). A TEVp truncated at amino
acid 218 was found functional and did not undergo auto-inhibition
(Nunn et al., 2005) while TEVp truncated at residue 219 was also
found effective in a controllable split-TEV system (N-TEV residues
1–118 and C-TEV residues 119–219) (Gray et al., 2010). Interest-
ingly, mutation of C-terminal residues SELVYSQ (236–242) with
NEGGGLE highly increased TEVp puriﬁcation through a C-terminal
6His-tag (Wu  et al., 2009), suggesting these modiﬁcations blocked
TEVp auto-cleavage.
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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Because of its remarkable speciﬁcity, stability and activity in
everal buffer conditions,  TEVp is widely used as a biotechnological
ool, for instance as a reagent for endoproteolytic removal of afﬁnity
ags (Melcher, 2000; Sun et al., 2012).
Expression of TEVp was found to be safe not only in bacterial,
east, plant and mammalian cells, but also in living organisms like
rosophila (Ceriani et al., 1998; Henrichs et al., 2005; Pauli et al.,
008; Satoh and Warren, 2008; Taxis et al., 2009)
During viral infection, TEVp accumulates mainly in the nucleus
f plant cells before being released from the full-length Nla precur-
or protein, while when expressed alone it largely localises in the
ytoplasm (Ceriani et al., 1998).
With the aim of targeting TEVp to the ER for biotechnological
pplications, we engineered a mutated version that showed strong
leavage activity on substrates localised to the ER lumen. Here we
how its ability to speciﬁcally clip a tag from membrane proteins
n living mammalian cells and to assist in the post-translational
aturation of a single ORF encoding the secretory L and H chains of
n IgG mAb, allowing proper assembly and secretion of the mature
nd functional H2L2 protein.
. Materials and methods
.1. Constructs
A codon-optimized version of TEVp was cloned into pcDNA3
pstream the SV5-tag (GKPIPNPLLGLD) and used as the basis to
erform all TEVp mutants, obtained by site-directed mutagenesis
QuikChange Site Directed Mutagenesis Kit, Stratagene), using
rimers: N23Q fw/rv (CTATCTGCCACCTGACTcAgGAAAGCGACG-
ACATACC/GGTATGTCCGTCGCTTTCcTgAGTCAGGTGGCAGATAG);
130S fw/rv (GTCTCCGACACCTCTTcTACATTCCCTTC-
AGTG/CACTAGAAGGGAATGTAgAAGAGGTGTCGGAGAC); T173G
w/rv (CCATTCAGCCAGCAACTTCggAAATACTAACAATTACTTCA-
CTC/(GAGGTGAAGTAATTGTTAGTATTTccGAAGTTGCTGGCTG-
ATGG); C110S fw/rv (GAGGGAGGAACGCATCaGCCTGGTGACTAC-
AACTTCC/GGAAGTTGGTAGTCACCAGGCtGATGCGTTCCTCCCTC).
TEVp was modiﬁed by inserting at the N-terminus the cod-
ng sequences of an immunoglobulin secretion signal (Li et al.,
997) and cloned into pcDNA3 vector, yielding sec-TEVp. Sec-TEVp
35 was obtained by substitution of the wild type (wt) C-terminal
equence with AACGAAGGGGGCCTGGAA.
The SV5-TS-MHC-I-roTag, and the SV5-MHC-I-TS-roTag
ere derived from a construct encoding the cDNA of the A2 allele of
he human MHC-I chain previously described (Petris et al., 2011),
ontaining at the N-terminus the coding sequences for a secre-
ion signal and the SV5 tag (GKPIPNPLLGLD) and at the C-terminus
he roTag tag (SISSSIFKNEG) (Petris et al., 2014a). The TEV cleav-
ge site (ENLYFQ/G) was included either in the ER luminal position
ownstream of SV5 or in the cytosolic tail just upstream roTag. The
onstruct for Tetherin (N65,92A) (Petris et al., 2014b), with a dele-
ion of the 20C-terminal residues that serve as a signal for the GPI
nchor was C-terminal tagged with SV5 followed by TS and roTag.
he single ORF pcDNA3 vector, encoding the full length L and H
hains from mAb  14F7 (Carr et al., 2000), was obtained by cloning
he coding sequences of the two chains (Rodríguez et al., 2007),
ngineered by the addition of an immunoglobulin secretion signal
eptide at the N-terminus and including the linker SSGSENLYFQGT
ith a TS (underlined) between the two chains.
.2. Cell culture and transfectionHEK-293T cells were cultured in Dulbecco’s modiﬁed Eagle’s
edium (DMEM, Life Technologies), supplemented with 10% fetal
alf serum (FCS, Life Technologies). Cells were transfected in 6-wellhnology 212 (2015) 159–166
plates (about 5 × 105 cells/well) by standard calcium phosphate
technique. Approximately 18 h after transfection, medium was
changed and cells were further incubated for at least 7–8 h, before
medium and cell harvesting. When indicated the proteasome
inhibitor MG132 (Sigma) was  added at a concentration of 10 M
for 4 h. P3 × 63 cells were cultured in RPMI medium (RPMI, Life
Technologies) supplemented with 10% fetal calf serum (FCS, Life
Technologies).
2.3. Cell extract preparation and western blotting
Transfected HEK-293T cells were washed with PBS and lysed
with SDS-lysis buffer (100 mM Tris–HCl, pH 6.8, 6% SDS, 30 mM
NEM, 1% protease inhibitors cocktail (Sigma)) and sonicated.
For SDS-PAGE samples were boiled 10 min  in SDS-gel-loading
buffer (25 mM Tris–HCl, pH 6.8, 1% SDS, 10% glycerol, 175 mM -
mercaptoethanol) before gel loading. Gels were blotted onto PVDF
membranes (Millipore), reacted with anti-SV5 (Life Technologies)
or anti-roTag (Petris et al., 2014a) mAb  followed by incubation
with a HRP-labeled anti-mouse whole IgG antibody (KPL) for ECL
detection. Where indicated, as loading or transfection control,
mouse anti--tubulin (Calbiochem) antibody was used followed
by appropriate HRP-labeled secondary antibody. Where indicated,
cellular lysates or eluted material were treated with Peptide-N-
Glycosidase-F (PNGase-F) or Endoglycosidase Hf (Endo-Hf) (New
England Biolabs) according to manufacturer instructions.
2.4. Cytoﬂuorimetric analysis
HEK-239T cells, co-transfected with sec-TEVp wt or QSG and
Tetherin-SV5-TS-roTag, were incubated with anti-SV5 tag mAb
(Invitrogen), or anti-roTag mAb  (Petris et al., 2014a) and then with
an Alexa Fluor® 488-conjugated goat anti-mouse IgG (Jackson).
P3 × 63 cells were incubated with puriﬁed 14F7 mAb  (Carr et al.,
2000) or with supernatants of cells expressing 14F7 mAb  from a sin-
gle polypeptide co-transfected or not with sec-TEVp QSG, followed
by ﬂuorescein-conjugated anti-mouse IgG (KPL) and analyzed in a
FACSCalibur (Becton Dickinson). mAb  1E10 (Vázquez et al., 1998)
was used as idiotype control.
2.5. Analysis of structures
TEVp mutants were evaluated on published TEVp structures
(PBD code: 1LVB and 1LVM (Phan et al., 2002)) using Swiss-
PdbViewer 4.0.4 or PyMOL.
3. Results
3.1. ER-targeted wild type TEVp is inactive in the secretory
pathway
In order to localise TEVp to the secretory pathway of mam-
malian cells (sec-TEVp), the enzyme was engineered by fusing at
the N-terminus a strong immunoglobulin signal peptide (Li et al.,
1997). The SV5-tag was  added to the C-terminus for detection. sec-
TEVp activity within the lumen of the ER was assayed in HEK-293T
cells by co-expression with a double-tagged MHC-I chain reporter
(≈48 kDa), previously used in other studies (Petris et al., 2011),
which contains the SV5 tag at the N-terminus (luminal side) and
roTag at the C-terminus cytosolic side (Petris et al., 2014a). A TS was
included downstream of SV5 in ER luminal position (Fig 1A). Upon
cleavage, SV5 is removed and the digested polypeptide (≈43 kDa)
can still be detected by anti-roTag mAb. Despite sec-TEVp was
well expressed migrating in SDS-PAGE as a 37 kDa band, no pro-
teolytic cleavage of the MHC-I reporter was observed (Fig. 1B).
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Fig. 1. Wild type TEVp is not active in the ER. (A) scheme of the MHC-I reporter construct with a cleavage site (TS) in luminal position. SV5 and roTag were used as tags at the
N-  and C-terminus. (B) WB  of cell extracts from 293T cells co-expressing MHC-I reporter and the indicated TEVp versions. Blots were developed for SV5 or roTag as indicated.
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mB  of the SV5-tagged TEVp is also shown. (C) schematic representation of the TEVp
23  and N171 shown in red and N52 and N68 in green. Peptide substrate is indicat
reated  with endo-glycosydases Endo-Hf and PNGase F. With exception of panel D 
s expected, the control cytosolic TEVp (cyt-TEVp) and the inac-
ive mutant C151A did not cleave the luminal TS (Fig. 1B). While
ec-TEVp was readily detected in cell extracts of transfected cells,
he non-ER-targeted cyt-TEVp was not because of its well-known
uto-cleavage activity, which leads to the removal of the C-terminal
ag. This result is consistent with lack of activity of sec-TEVp in
he ER lumen. The expected apparent molecular mass of cyt-TEVp
s 26 kDa, as observed for the cyt-C151A mutant, while the one
bserved for sec-TEVp was of ≈37 kDa, as a consequence of N-
lycosylations. In fact, four potential N-glycosylation sites (NXS/T,
here X is any amino acid except P) are present in TEVp primary
equence, localised in various regions of the enzyme structure (N23,
52, N68, and N171) (Fig. 1C), which can account for the altered
AGE migration. Indeed, post-lysis treatment with glycosidases
ndo-Hf and PNGase-F resulted in the expected 26 kDa protein
Fig 1D). N-glycosylation is also likely one of the main reasons that
mpair sec-TEVp activity in the ER lumen as two N-glycosylation
ites, N23 and N171, could compromise correct folding: N23 is
uried inside the TEVp molecule, while N171 is in close proximity
o the catalytic pocket (Fig 1C, labeled in red). In contrast, glycosyla-
ion of N52 and N68 that are exposed on the folded TEVp structure
nlikely affect enzymatic activity (Fig. 1C, labeled in green).
.2. Engineering an active sec-TEVpTo design an active sec-TEVp variant, we took into consider-
tion the two major post-translational modiﬁcations of proteins
n the ER lumen: N-glycosylation and cysteine oxidation, which
ay  hamper correct folding of sec-TEVp. Four different cysteinesture (adapted from pdb ﬁle 1LVB, (Phan et al., 2002)) with the N-glycosylation sites
ight blue. (D) WB  of cell extracts from HEK 293T cell transfected with wt sec-TEVp
re representative of at least three independent experiments.
(C19, C110, C130, and C151) are present in TEVp primary sequence,
of which C151 is in the catalytic site. Considering solvent acces-
sibility in the TEVp structure (1LVB, (Phan et al., 2002)), C130 is
the most exposed one, while side chains of C19 and C110 are
buried within the molecule. In addition, residue C130 is highly
reactive: in diverse crystal structures it either forms a disulphide
bridge between TEVp molecules or reacts with -mercaptoethanol
present in solution (Nunn et al., 2005). We  therefore tested a panel
of sec-TEVp mutants (schematically shown in Fig. 2A) in HEK-293T
cells using the TS-tagged MHC-I reporter. As shown in Fig 2B,
similarly to wild type (wt) sec-TEVp and the catalytically inac-
tive C151A, the single mutants N23Q and C130S with apparent
molecular masses of 35 and 37 kDa, respectively, did not cleave the
reporter, while the double mutants N23Q-C130S (QS) and C130S-
T173G (SG) (both of ≈35 kDa) showed only partial activity (Fig. 2B,
lanes 5, 6). To prevent N-glycosylation at N171, the mutation of
T173 into glycine was  preferred, because the alternative N171Q
mutation was detrimental for sec-TEVp activity (Fig 2B, lane 10). In
fact, a variant containing the three mutations N23Q-C130S-T173G
(QSG) (≈35 kDa) completely cleaved the MHC-I reporter (Fig 2B,
lane 7 and 9). Addition of the C110S mutation into sec-TEVp QSG
variant had a deleterious effect on its activity (Fig 2B, lane 8). Sim-
ilarly, mutation C19S blocked TEV activity (not shown). Further
demonstration of the QSG cleavage activity in the ER lumen was
obtained with BST-2/Tetherin, a different membrane reporter pro-
tein. Tetherin is a dimeric type II trans-membrane protein stabilised
by three disulﬁde bonds between the two  parallel monomers with a
GPI anchor at the C-terminus that is well expressed and exposed on
the cell surface. This is also true for the non-glycosylated (N65,92A)
162 F. Cesaratto et al. / Journal of Biotechnology 212 (2015) 159–166
Fig. 2. A sec-TEVp mutant active in the ER lumen. (A) schematic representation of the relevant residues in the wild type (wt) TEVp sequence, mutated into the indicated
amino  acids in the different sec-TEVp versions. C151, indicated in red is essential for catalytic activity. (B) WB developed with SV5 or roTag of the MHC-I reporter with
TS  in luminal position, co-expressed with the indicated sec-TEVp mutants. Arrowhead indicates un-cleaved reporter; arrow cleaved reporter. (C) scheme of the Tetherin
reporter  construct with a cleavage site (TS) in luminal position, between SV5 and the C-terminal roTag. (D) WB of extracts from cells co-expressing Tetherin-SV5-TS-roTag
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xperiments.
utant (≈24 kDa) with the GPI acceptor sequence replaced by the
V5-TS-roTag double-tag sequence (Fig. 2C). sec-TEVp QSG efﬁ-
iently cleaved Tetherin molecules bearing the TS (cleaved Tetherin
22 kDa), as shown by WB  (Fig. 2D) and cytoﬂuorimetry (Fig. 2E).
.3. Activity of TEVp mutants in the cytosol.
The sec-TEVp mutants QS and QSG were the two most active
nes in the ER lumen. To compare their activity with wt cyt-TEVp
nd the largely used mutants S219 V and S219P (reported to have
educed auto-cleavage activity), we directly co-expressed them in
he cytosol of HEK-293T cells (by removing the sec signal peptide)
ith an MHC-I reporter containing the TS in the cytosolic tail just
pstream of roTag (≈48 kDa) (Fig. 3A). As shown in Fig. 3B, wt  cyt-
EVp and mutants S219 V and QS digested almost completely the
eporter MHC-I to a 45 kDa fragment and they were themselves
uto-cleaved. In comparison, mutant QSG was slightly less efﬁcient
n the cytosol and not completely auto-cleaved. It was expressed
t levels comparable to mutant S219P, reported to be very stableherin-SV5-TS-roTag with sec-TEVp wt or QSG variant, analysed with anti-SV5 (left
ody. Blots and cytoﬂuorimetric analysis are representative of at least 3 independent
(Kapust et al., 2001), but QSG mutant was  clearly more efﬁcient, as
S219P cleaved only around 50% of the MHC-I reporter.
Interestingly, while wt cyt-TEVp did not cleave the lumi-
nal TS, sec-TEVp variants including the wt were able to cleave
(albeit partially) the reporter MHC-I with TS in the cytosolic tail
(Fig. 3C). They also showed, as expected, different levels of N-
glycosylation. The cytosolic activities of sec-TEVp enzymes targeted
to the ER lumen are most likely due to the fraction of molecules
spontaneously targeted to the ER-associated degradation path-
way (ERAD). Molecules entering ERAD are retro-translocated to
the cytosol, where they become de-glycosylated by the endoge-
nous cytosolic PNGase before proteasomal degradation (Misaghi
et al., 2004). As N-glycosylation prevented wt  sec-TEVp activity
in the ER lumen, it was  expected that the de-glycosylated frac-
tions resulted in an active enzyme. In fact, de-glycosylated wt
sec-TEVp accumulated in the cytosol upon treatments of cells with
MG132, which blocks degradation by the proteasome (Fig. 3D).
Consistently, mutant QSG with two N-glycosylations sites mutated
showed higher relative activity in the cytosol (Fig. 3C, lane 6).
F. Cesaratto et al. / Journal of Biotechnology 212 (2015) 159–166 163
Fig. 3. Activity of sec-TEVp mutants in the cytosol. (A) Scheme of the MHC-I reporter with TS in cytosolic position. (B) WB of the MHC-I reporter co-expressed with
TEVp  mutants expressed in the cytosol (without leader peptide). Arrowhead indicates un-cleaved reporter; arrow cleaved reporter. (C) WB of the MHC-I reporter with
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ndependent experiments.
.4. Functional un-cleavable versions
The ER-active QSG mutant showed partial auto-cleavage activ-
ty. We  thus tested two alternative QSG versions differing in the
-terminal end: one corresponding to the truncated form (end-
ng with M218, sec-TEVp QSG-218) and one in which the TEVp
-terminus (from M235) was changed (residues 236–242) from
ELVYSQ to MNEGGLE (sec-TEVp QSG-235), similarly to mutations
ntroduced in the TEVp C-terminus to improve its puriﬁcation (Wu
t al., 2009). As shown in Fig. 4A, both variants showed activity in
he ER lumen on the MHC  reporter (Fig. 4A, lanes 5, 6) and reduced
uto-cleavage (shown only for mutant 235, as the 218 was  not
agged). Interestingly, in agreement with a previous report with
hortened TEVp (Nunn et al., 2005), the truncated QSG-218 form
as active both in the ER (Fig. 4A, lane 5) and in the cytosol (Fig. 4B,
ane 3). In addition, the cytosolic wt-235 and QSG-235 versions
acked auto-cleavage activity while remaining fully active on the
ytosolic reporter substrate (Fig. 4B, lanes 4, 6). In contrast to sec-
EVp wt and sec-TEVp wt-235, which were not secreted (and not
ctive), sec-TEVp QSG-235 was found actively secreted in the cell
ulture supernatant (Fig. 4C, lanes 1, 2 and 5, 6). We  expect sec-
EVp QSG-218 to be also actively secreted (since it is not tagged it
ould not be conﬁrmed), as it has the same glycosylation muta-
ions of sec-TEVp QSG-235. As reported above, the QSG variant
etained auto-cleavage activity and was therefore undetectable in
he supernatant.ants. Arrow indicates un-cleaved reporter; arrowhead cleaved reporter. (D) WB of
owhead indicates de-glycosylated sec-TEVp. Blots are representative of at least 3
3.5. Functional maturation of a single chain mAb  by mutant QSG
The activity of sec-TEVp QSG was further tested on the
expression of the model full-length IgG monoclonal antibody
(mAb) 14F7, which recognises the N-glycosylated GM3  ganglioside
(GM3(Neu5Gc)) (Carr et al., 2000). We  prepared a construct with a
single ORF encoding an N-terminal signal peptide (sec) followed by
the full-length L and H chains of the IgG antibody that were sepa-
rated by the 7-amino acid-long TS (schematically shown in Fig. 5A).
We expected that upon co-expression with the ER-functional QSG
mutant, the single polypeptide would be cleaved into the two func-
tional chains (L and H), thus allowing proper IgG assembly and
secretion. As shown in Fig. 5B, in the presence of the active QSG
protease the single polypeptide of around 75 kDa was found fully
cleaved into the two  chains (L: 25 kDa; H: 50 kDa) both in cellu-
lar extracts and supernatants, while in the absence of the protease
the two chains remained fused. The secreted material was mostly
formed by the expected 150 kDa of the fully assembled H2L2, as
shown in a non-reducing WB (Fig. 5B, right panel). Surprisingly,
the un-cleaved L-H was  also found secreted. However, the mature
(cleaved) 14F7 IgG produced by cells co-expressing the QSG  mutant
was able to bind the antigen on the surface of P3 × 63 cells, while
the signal with the un-cleaved one was very low (Fig. 5C). Thus, the
active sec-TEVp QSG is a valuable tool to speciﬁcally and efﬁciently
cleave functional polypeptides into the ER lumen without affecting
assembly and secretion.
164 F. Cesaratto et al. / Journal of Biotechnology 212 (2015) 159–166
Fig. 4. TEVp un-cleavable versions. (A) WB showing activity of sec-TEVp wt and
QSG mutants with modiﬁed C-termini on the MHC-I reporter with TS in luminal
position (upper panels) and resistance to auto-cleavage. (B) WB  showing activity
of  cyt-TEVp wt and QSG mutants with modiﬁed C-termini on the MHC-I reporter
with TS in cytosolic position (upper panels) and resistance to auto-cleavage. (C)
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Fig. 5. Processing and maturation of a full antibody molecule translated from a
single ORF upon co-expression with sec-TEVp QSG variant. (A) schematic represen-
tation of the construct encoding in a single ORF the full-length mAb  14F7. L and
H  chains are separated by TS. A single signal peptide (sec) was present at the N
terminus of the polyprotein. Upon co-expression with the ER active sec-TEVp QSG
mutant the two  processed L and H chains assembled into a mature H2L2 species. (B)
WB  of cellular extracts or supernatants of the sec-L-(TS)-H construct after expres-
sion  without or with the sec-TEVp QSG. Supernatants were run under reducing and
non-reducing conditions, as indicated. (C) Cytoﬂuorimetric analysis of P3 × 63 cells
that  reacted with puriﬁed mAb  14F7 (positive control), or with supernatants from
cells transfected with the 14F7 sec-L-(TS)-H construct alone (un-cleaved) or withB  of cell extracts (E) and supernatants (S) from cells expressing sec-TEVp wt-235
nd variants QSG and QSG-235. Blots are representative of at least 3 independent
xperiments.
. Discussion
TEVp has been widely used both for in vitro applications and
n vivo studies by expressing it in the cytoplasm to process pro-
eins with a cleavage site (Ceriani et al., 1998; Henrichs et al., 2005;
elcher, 2000; Pauli et al., 2008; Satoh and Warren, 2008; Sun
t al., 2012; Taxis et al., 2009). We  observed, however, that the
t enzyme could not be similarly exploited within the secretory
athway by targeting it to the ER via a secretion signal peptide
t the N-terminus, as it was totally inactive on luminal substrate
roteins harboring a TS. We  speculated this was due to inactiva-
ion by characteristic post-translational modiﬁcations occurring
n the ER environment, such as N-glycosylation and cysteinesec-TEVp QSG (mature) followed by an Alexa488-conjugated goat anti-mouse anti-
body. Blots and cytoﬂuorimetric analysis are representative of at least 3 independent
experiments.
oxidation. In fact, two N-glycosylations at N23 and N171 were
able to strongly impair sec-TEVp activity in the ER lumen. Of note,
while the conservative mutation of N23 into Q was well tolerated,
the same type of replacement in position 171 was  much more
critical due to involvement of N171 in interactions with the sub-
strate (Phan et al., 2002). In fact, the sec-TEVp N171Q was  almost
inactive within the ER lumen. In silico simulation of N171Q substi-
tution showed that the bulkier glutamine side chain clashed with
either the substrate or other TEVp residues in almost all theoretical
isomeric conformations, consistent with the experimental results.
Conversely, mutation of the surface-exposed residue T173 into
glycine was predicted to have no adverse effect on protein struc-
ture, while preventing N171 glycosylation, as we  experimentally
observed. Interestingly, in contrast to our ﬁndings in mammalian
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ells, it was recently reported a screening of sec-TEVp mutants in
east, where even wild type sec-TEVp was found to be active in
he ER (Yi et al., 2013). This could be the consequence of lower N-
lycosylation efﬁciency in yeast cells upon over-expression of the
ec-TEVp.
Mutation of C130 into S also improved TEVp activity in the
R lumen, most likely due to interference of this highly exposed
esidue with enzyme folding in the oxidising environment of the ER
umen. Mutation of other cysteines such as C19S and C110S, which
re internally localised within the TEVp structure had deleterious
ffects on sec-TEVp activity.
Interestingly, the three mutations we selected that allowed
EVp activity in the ER lumen were not detrimental for its activ-
ty in the cytosol. In particular, cyt-TEVp mutations N23Q, C130S
nd T273G were much more active and similarly resistant to
uto-cleavage in cells, compared to the S219P mutant, previously
laimed to have higher stability (Kapust et al., 2001; Yi et al., 2013).
Our data conﬁrmed that the TEVp truncated form (variant 218)
s active in living cells, although slightly less than the full-length
EVp. Substitution of the C-terminal 236-242 sequence SELVYSQ
ith NEGGLEG (variant 235) also prevented TEVp self-cleavage
ithout impairing enzymatic activity.
Unexpectedly, our experiments showed that sec-TEVp is recog-
ized as a substrate of the ERAD pathway and retro-translocated
rom the ER lumen to the cytosol, where it was  found de-
lycosylated and active on a TS localised in the MHC-I cytosolic
ail, before its degradation. As shown here for MHC-I or Tetherin,
o-expression of sec-TEVp QSG with a TS-tagged protein can be
sed to determine localisation within the secretory pathway.
A TEV protease functionally active along the secretory pathway
an have several applications. Here, for example, we  report the
orrect assembly and secretion of the two chains of the complete
gG mAb  14F7 originally translated from a single ORF, upon co-
xpression with the sec-TEVp QSG. This exclusive sec-TEVp variant
ould be used to conditionally activate pro-enzymes or inactivate
rotein molecules or complexes within the secretory pathway, as
t has been done in the cytosol (Gray et al., 2010; Konno et al., 2011;
ang et al., 2010). The principle of cleavage of a single translated
RF encoding distinct subunits represents a precise way  to achieve
quimolar expression of two or more polypeptides, as it is the case
f the H and L chains of the IgG, as an alternative to strategies based
n translation of bicistronic mRNAs encoding the viral peptide 2A
Piperno et al., 2015; Principe et al., 2015; Sharma et al., 2012).
owever, it remains to be determined the efﬁciency of IgG assem-
ly into mature H2L2 molecules in conditions of strict 1:1 molar
atio of each polypeptide, as in the case here described, as opposed
o conditions in which L chain is expressed in excess in relation to
he H chain.
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